Incyte Biosciences Canada today announced that Health Canada has approved Opzelura® (ruxolitinib (as ruxolitinib phosphate)) ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well ...

Roflumilast cream 0.05% is approved for children aged 2 to 5 with mild to moderate atopic dermatitis, offering a steroid-free ...

In a single-center retrospective observational study at the Bari Polyclinic, researchers analyzed 50 adults with non-segmental vitiligo affecting 0.5 to 10% of their body surface area, including the ...

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...

The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...

Allure Best of Beauty Award Seal 2025 Allure Best of Beauty Award Seal 2025 First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent ...

The FDA approved Zoryve cream 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis, ...